• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Arbutus Biopharma Corporation

    9/11/23 5:07:11 PM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABUS alert in real time by email
    SC 13G 1 arbutus13g-090123.htm
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C.  20549
    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. __ )*
    Arbutus Biopharma Corporation
    (Name of Issuer)
    Common Shares, without par value
    (Title of Class of Securities)
    03879J100
    (CUSIP Number)
    September 1, 2023
    (Date of Event which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [ ]            Rule 13d-1(b)
    [x]            Rule 13d-1(c)
    [ ]            Rule 13d-1(d)
    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).





    1.
    NAMES OF REPORTING PERSONS
       
     
    Whitefort Capital Management, LP
       
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
     
    (a)    [ ]
     
    (b)    [ ]
       
    3.
    SEC USE ONLY
       
    4.
    CITIZENSHIP OR PLACE OF ORGANIZATION
       
     
    Delaware
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
       
    5.
    SOLE VOTING POWER
       
     
    0
       
    6.
    SHARED VOTING POWER
       
     
    10,013,899
       
    7.
    SOLE DISPOSITIVE POWER
       
     
    0
       
    8.
    SHARED DISPOSITIVE POWER
       
     
    10,013,899
       
    9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     
    10,013,899
       
    10.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)   [ ]
       
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     
    6.0%
       
    12.
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
     
    PN, IA
     
     


    1.
    NAMES OF REPORTING PERSONS
       
     
    David Salanic
       
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
     
    (a)    [ ]
     
    (b)    [ ]
       
    3.
    SEC USE ONLY
       
    4.
    CITIZENSHIP OR PLACE OF ORGANIZATION
       
     
    France
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
       
    5.
    SOLE VOTING POWER
       
     
    0
       
    6.
    SHARED VOTING POWER
       
     
    10,013,899
       
    7.
    SOLE DISPOSITIVE POWER
       
     
    0
       
    8.
    SHARED DISPOSITIVE POWER
       
     
    10,013,899
       
    9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     
    10,013,899
       
    10.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)   [ ]
       
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     
    6.0%
       
    12.
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
     
    IN, HC
     
     


    1.
    NAMES OF REPORTING PERSONS
       
     
    Joseph Kaplan
       
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
     
    (a)    [ ]
     
    (b)    [ ]
       
    3.
    SEC USE ONLY
       
    4.
    CITIZENSHIP OR PLACE OF ORGANIZATION
       
     
    United States
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
       
    5.
    SOLE VOTING POWER
       
     
    0
       
    6.
    SHARED VOTING POWER
       
     
    10,013,899
       
    7.
    SOLE DISPOSITIVE POWER
       
     
    0
       
    8.
    SHARED DISPOSITIVE POWER
       
     
    10,013,899
       
    9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     
    10,013,899
       
    10.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)   [ ]
       
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     
    6.0%
       
    12.
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
     
    IN, HC





    Item 1(a).
    Name of Issuer:
    Arbutus Biopharma Corporation (“Issuer”)
    Item 1(b).
    Address of Issuer’s Principal Executive Offices:
    701 Veterans Circle
    Warminster, PA 18974
    Item 2(a).
    Name of Persons Filing:
    The names of the persons filing this statement on Schedule 13G are (collectively, the “Reporting Persons”):

    •
    Whitefort Capital Management, LP, a Delaware limited partnership (“Whitefort Management”);


    •
    David Salanic, a French citizen (“Mr. Salanic”); and


    •
    Joseph Kaplan, a United States citizen (“Mr. Kaplan”).

    Whitefort Management acts as the investment manager of certain client accounts. Each of Mr. Salanic and Mr. Kaplan is a Co-Managing Partner of Whitefort Management.
    By virtue of these relationships, each of Whitefort Management, Mr. Salanic and Mr. Kaplan may be deemed to have voting and dispositive power with respect to shares of Common Stock (as defined below) held in client accounts managed by Whitefort Management.
    Item 2(b).
    Address of Principal Business Office or, if None, Residence:
    The principal business address of each of the Reporting Persons is 12 East 49th Street, 40th Floor, New York, New York 10017.
    Item 2(c).
    Citizenship:
    Mr. Salanic is a citizen of France.
    Mr. Kaplan is a citizen of the United States.
    Whitefort Management is a limited partnership formed under the laws of the State of Delaware.
    Item 2(d).
    Title of Class of Securities:
    Common Shares, without par value (the “Shares”)
    Item 2(e).
    CUSIP Number:
    03879J100
    Item 3.
    If This Statement is Filed Pursuant to Rule 13d 1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
     
    (a)
    [ ]
    Broker or dealer registered under Section 15 of the Exchange Act.
           
     
    (b)
    [ ]
    Bank as defined in Section 3(a)(6) of the Exchange Act.
           


     
    (c)
    [ ]
    Insurance company defined in Section 3(a)(19) of the Exchange Act.
           
     
    (d)
    [ ]
    Investment company registered under Section 8 of the Investment Company Act.
           
     
    (e)
    [ ]
    Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
           
     
    (f)
    [ ]
    Employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
           
     
    (g)
    [ ]
    Parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
           
     
    (h)
    [ ]
    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
           
     
    (i)
    [ ]
    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
           
     
    (j)
    [ ]
    Non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J).
           
     
    (k)
    [ ]
    Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).  If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

    Item 4.
    Ownership.
    (a)
    Amount beneficially owned:
    As of the close of business on September 11, 2023,

    (i)
    Whitefort Management, as the investment manager of certain client accounts, may be deemed to beneficially own the 10,013,899 Shares held in such accounts;


    (ii)
    Mr. Salanic, as a Co-Managing Partner of Whitefort Management, may be deemed to beneficially own the 10,013,899 Shares held in the client accounts managed by Whitefort Management.


    (iii)
    Mr. Kaplan, as a Co-Managing Partner of Whitefort Management, may be deemed to beneficially own the 10,013,899 Shares held in the client accounts managed by Whitefort Management.

    (b)
    Percent of Class:
    The percentage of Shares reported owned by each person named herein is based upon 167,556,661 Shares outstanding as of August 1, 2023, as reported on the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 3, 2023. As of the close of business on September 11, 2023, each of the Reporting Persons may be deemed to beneficially own 6.0% of the outstanding Shares.
    (c)
    Number of shares as to which such person has:

    (i)
    Sole power to vote or to direct the vote:
    See Cover Pages Items 5-8.

    (ii)
    Shared power to vote or to direct the vote:
    See Cover Pages Items 5-8.

    (iii)
    Sole power to dispose or to direct the disposition:
    See Cover Pages Items 5-8.



    (iv)
    Shared power to dispose or to direct the disposition:
    See Cover Pages Items 5-8.
    Item 5.
    Ownership of Five Percent or Less of a Class.
    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following [  ].
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.
    Not applicable.
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
    Not applicable.
    Item 8.
    Identification and Classification of Members of the Group.
    See Exhibit A.
    Item 9.
    Notice of Dissolution of Group.
    Not applicable.
    Item 10.
    Certification.
    By signing below each of the undersigned certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURES
    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.
    Dated: September 11, 2023
    WHITEFORT CAPITAL MANAGEMENT, LP
     
    By:
    /s/ David Salanic
     
    David Salanic, Co-Managing Partner
     
     

     
    By:
    /s/ Joseph Kaplan
     
    Joseph Kaplan, Co-Managing Partner

    /s/ David Salanic
    DAVID SALANIC

    /s/ Joseph Kaplan
    JOSEPH KAPLAN



    EXHIBIT A
    JOINT FILING AGREEMENT
    The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Shares, without par value, of Arbutus Biopharma Corporation dated September 11, 2023 and any further amendments thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.
    Dated: September 11, 2023
    WHITEFORT CAPITAL MANAGEMENT, LP
     
    By:
    /s/ David Salanic
     
    David Salanic, Co-Managing Partner
     
     

     
    By:
    /s/ Joseph Kaplan
     
    Joseph Kaplan, Co-Managing Partner

    /s/ David Salanic
    DAVID SALANIC

    /s/ Joseph Kaplan
    JOSEPH KAPLAN


    Get the next $ABUS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABUS

    DatePrice TargetRatingAnalyst
    3/4/2022$5.50 → $6.00Buy
    Chardan Capital
    2/2/2022$4.00 → $5.00Hold → Buy
    Jefferies
    11/8/2021$7.00 → $9.00Market Outperform
    JMP Securities
    More analyst ratings

    $ABUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form 4 filed by Chief Financial Officer Nguyen Tuan

      4/A - Arbutus Biopharma Corp (0001447028) (Issuer)

      4/1/25 5:47:47 PM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Nguyen Tuan

      4 - Arbutus Biopharma Corp (0001447028) (Issuer)

      3/31/25 4:24:03 PM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Nguyen Tuan

      3 - Arbutus Biopharma Corp (0001447028) (Issuer)

      3/31/25 4:21:38 PM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABUS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital reiterated coverage on Arbutus Biopharma with a new price target

      Chardan Capital reiterated coverage of Arbutus Biopharma with a rating of Buy and set a new price target of $6.00 from $5.50 previously

      3/4/22 8:38:50 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arbutus Biopharma upgraded by Jefferies with a new price target

      Jefferies upgraded Arbutus Biopharma from Hold to Buy and set a new price target of $5.00 from $4.00 previously

      2/2/22 5:11:07 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities reiterated coverage on Arbutus Biopharma with a new price target

      JMP Securities reiterated coverage of Arbutus Biopharma with a rating of Market Outperform and set a new price target of $9.00 from $7.00 previously

      11/8/21 7:11:01 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Arbutus Biopharma Corporation

      SC 13G/A - Arbutus Biopharma Corp (0001447028) (Subject)

      11/14/24 8:41:06 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Arbutus Biopharma Corporation

      SC 13G - Arbutus Biopharma Corp (0001447028) (Subject)

      6/10/24 4:50:25 PM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Arbutus Biopharma Corporation (Amendment)

      SC 13D/A - Arbutus Biopharma Corp (0001447028) (Subject)

      5/17/24 9:03:23 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABUS
    SEC Filings

    See more
    • Arbutus Biopharma Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Arbutus Biopharma Corp (0001447028) (Filer)

      5/23/25 4:08:10 PM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Arbutus Biopharma Corporation

      10-Q - Arbutus Biopharma Corp (0001447028) (Filer)

      5/14/25 5:21:13 PM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arbutus Biopharma Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Arbutus Biopharma Corp (0001447028) (Filer)

      5/14/25 7:31:11 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABUS
    Financials

    Live finance-specific insights

    See more
    • Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update

      Imdusiran data from IM-PROVE I and IM-PROVE II Phase 2a clinical trials to be presented at upcoming AASLD - The Liver Meeting 2024 Multiple-ascending doses of AB-101 in healthy subjects in the Phase 1a/1b clinical trial were generally safe and well-tolerated with evidence of receptor occupancy Now dosing cHBV patients with AB-101 in Part 3 of the Phase 1a/1b clinical trial Cash runway into the fourth quarter of 2026Conference Call and Webcast Today at 8:45 AM ET WARMINSTER, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a f

      11/6/24 7:30:00 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

      WARMINSTER, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), ("Arbutus" or the "Company") a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its third quarter 2024 financial results and corporate update for Wednesday, November 6, 2024. The schedule for the press release and conference call/webcast are as follows: • Q3 2024 Press Release:Wednesday, November 6, 2024 at 7:30 a.m. ET• Q3 2024 Conference Call/Webcast:Wednesday, November 6, 2024 at 8:45 a.m. ET   To dial-in for the conference call

      10/23/24 7:30:00 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update

      End-of-treatment data presented at the EASL Congress from two Phase 2a clinical trials supports advancing imdusiran as a potential cornerstone in a HBV functional cure treatment regimen IM-PROVE I clinical trial demonstrated undetectable HBsAg in 33% of patients who were treated with 48 weeks of imdusiran and 24 weeks of IFN and in 67% of these patients with baseline HBsAg less than 1000 IU/mL Prioritizing imdusiran Phase 2b clinical development; eliminating HBV discovery efforts resulting in a reduction in workforce by 40% and extension of expected cash runway into the fourth quarter of 2026 Conference Call and Webcast Today at 8:45 AM ET WARMINSTER, Pa., Aug. 01, 2024 (GLOBE

      8/1/24 7:30:00 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABUS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Imdusiran combination therapy has functionally cured 8 patients with chronic hepatitis B (cHBV) to date, including 2 patients who received no interferon AB-101, oral small-molecule PD-L1 inhibitor, shown generally safe and well-tolerated with evidence of high receptor occupancy in Phase 1a/1b Andrew J. Sung joins Arbutus as General Counsel, bringing more than $28 billion in life sciences deal experience Strong financial position with cash, cash equivalents and marketable securities of $113M WARMINSTER, Pa., May 14, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease,

      5/14/25 7:30:00 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

      Data highlighted in late-breaker poster presentation shows that imdusiran achieves functional cure in chronic hepatitis B (cHBV) patients when combined with VTP-300 and low dose nivolumab In a Phase 1a/1b clinical trial, AB-101, an oral PD-L1 inhibitor, has shown to be generally safe and well-tolerated with evidence of high receptor occupancy and no liver dysfunction in cHBV patients WARMINSTER, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the presentation of five posters, including one late-breaker, highlighting imdusiran, its RNAi

      5/7/25 2:01:00 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

      Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S. mRNA-LNP vaccine litigation scheduled for September 2025 Reviewing pipeline and development plans for HBV programs Continued focus on efficient deployment of financial resources and personnel – terminated ATM program and implemented reduction of workforce by 57% in Q1 2025 Board has approved further changes to executive leadership team; including the appointment of Tuan Nguyen as Chief Financial Officer Strong financial position with cash, cash equivalents and investments in marketable securities of $123M WARMINSTER, Pa., March 27, 2025 (GLO

      3/27/25 7:30:00 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABUS
    Leadership Updates

    Live Leadership Updates

    See more
    • Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

      Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S. mRNA-LNP vaccine litigation scheduled for September 2025 Reviewing pipeline and development plans for HBV programs Continued focus on efficient deployment of financial resources and personnel – terminated ATM program and implemented reduction of workforce by 57% in Q1 2025 Board has approved further changes to executive leadership team; including the appointment of Tuan Nguyen as Chief Financial Officer Strong financial position with cash, cash equivalents and investments in marketable securities of $123M WARMINSTER, Pa., March 27, 2025 (GLO

      3/27/25 7:30:00 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

      WARMINSTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) --  Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease, today announced changes to its board of directors and the appointment of Lindsay Androski, J.D., M.B.A., as Chief Executive Officer. Ms. Androski replaces Michael J. McElhaugh, the Company's Interim President and CEO, effective immediately. Ms. Androski will also serve as a member of the Company's board of directors. Ms. Androski is an MIT-trained biologist with nearly 30 years of experience in the areas of biotechnology, law and academia. She has served in a variety of roles at Roivant. She

      2/25/25 7:00:00 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

      WARMINSTER, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that after a distinguished 38-year career, the Company's co-founder and Chief Scientific Officer, Dr. Michael Sofia, will retire effective December 31, 2024. Dr. Sofia is a globally recognized, Lasker award-winning antiviral drug discovery and development scientist. "On behalf of the entire Company, I want to thank Mike, a renowned industry veteran, for his tremendous contribu

      5/2/24 7:25:00 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care